Company Filing History:
2 out of 16 
2 out of 158 
6 out of 832,912 Years Active: 1995-2018
Title: Innovator in Viral Research: Chil-Yong Kang
Introduction
Chil-Yong Kang is a distinguished inventor based in London, Canada, known for his significant contributions to the field of virology. With a total of 10 patents to his name, his work focuses on developing modified matrix proteins of the vesicular stomatitis virus (VSV), showcasing a remarkable ability to innovate in vaccine research and immune response mechanisms.
Latest Patents
Kang's recent patents include critical advancements such as the development of mutant M proteins of vesicular stomatitis virus. One noteworthy invention involves modifying the matrix (M) protein, where specific amino acid changes were made: a glycine changed to a glutamic acid at position 21, a leucine changed to alanine at position 111, and a methionine changed to an arginine at position 51. Another variant includes a glycine to glutamic acid change at position 22 and two methionine residues altered at positions 48 and 51. These innovative recombinant VSVs demonstrate significant attenuation and lost virulence, providing a basis for vaccines that can evoke immune responses against targeted antigens. Additionally, the mutant strains are able to replicate efficiently at lower temperatures while exhibiting poor replication capabilities at higher temperatures.
Career Highlights
Chil-Yong Kang has made a mark in the industry by working with noteworthy organizations, including Korea Greencross Corporation, where he obtained valuable experience that has contributed to his innovative research and development in vaccines. His consistent focus on the intersection of viral protein modification and vaccine efficacy has made significant impacts in the scientific community.
Collaborations
Throughout his career, Kang has collaborated with various talented individuals, including Gyoung Nyoun Kim and Lizhong Luo. These collaborations have enabled the exchange of ideas and enhanced the development of pioneering technologies in the field of viral research.
Conclusion
Chil-Yong Kang stands out as a leading inventor in the domain of virology, with a solid portfolio of patents that demonstrate both his innovative spirit and dedication to advancing vaccine technology. His work on modified matrix proteins of vesicular stomatitis virus represents a significant leap forward in creating effective vaccines capable of addressing viral diseases. As he continues to explore new frontiers in scientific research, the impact of his inventions is likely to resonate within both academic and medical spheres for years to come.